布拉酵母菌联合奥美拉唑阿莫西林克拉霉素治疗顽固性幽门螺杆菌感染的临床研究  

Triple therapy regimen of Saccharomyces boulardii combined with Omeprazole,Amoxycillin and Clarithromycin in treatment of persistent Helicobacter pylori infection

作　　者：林光勇[1] 李菁[1] 林晓晓[1] 林正锋[1] 

机构地区：[1]温州医学院附属第二医院育英儿童医院药学部,浙江温州325027

出　　处：《中国微生态学杂志》2012年第4期341-342,共2页Chinese Journal of Microecology

摘　　要：目的探讨布拉酵母菌联合奥美拉唑阿莫西林克拉霉素三联疗法对幽门螺杆菌(Helicobacter pylori,H.pylori)顽固性感染的治疗效果。方法将120例H.pylori顽固性感染患者分成两组,分别采用奥美拉唑的三联疗法和布拉酵母菌联合奥美拉唑三联疗法治疗14 d。结果两组患者治疗14 d后,奥美拉唑三联组和布拉酵母菌联合奥美拉唑三联组的H.pylori清除率分别是94.6%和96.6%,两组间差异无统计学意义;在不良反应方面,奥美拉唑三联治疗组中发生16例,明显高于布拉酵母菌联合奥美拉唑三联组的5例(P<0.05)。结论布拉酵母菌联合奥美拉唑三联治疗方案不仅具有良好的H.pylori清除效果,而且不良反应少,是治疗顽固性H.pylori感染患者比较好的方法。Objective To evaluate the method for treatment of persistent Helicobacter pylori（H.pylori） infection.Method 120 patients with persistent H.pylori infection were divided into two groups,and treated with OAC triple therapy regimen（Omeprazole,Amoxycillin and Clarithromycin） and B＋OAC therapy regimen（Boulardii,Omeprazole,Amoxycillin and Clarithromycin）,respectively.Result H.pylori eradication rates were 94.6% and 96.6% in OAC group and B＋OAC group,respectively（P0.05）.However,the patients experiencing side-effects in OAC group were much more than those in B＋OAC group（16 patients vs.5 patients）（P0.05）.Conclusion Saccharomyces boulardii,Omeprazole,Amoxycillin and Clarithromycin therapy regimen is a better way for the treatment of persistent H.pylori infection because of its better tolerance in patients.

关 键 词：布拉酵母菌 奥美拉唑阿莫西林克拉霉素 幽门螺杆菌 

分 类 号：R969.3[医药卫生—药理学]